Pathogenesis, animal models and therapeutics in spinal and bulbar muscular atrophy (SBMA).
about
Androgen-modulating agents for spinal bulbar muscular atrophy/Kennedy's diseaseAndrogen-dependent pathology demonstrates myopathic contribution to the Kennedy disease phenotype in a mouse knock-in modelNeurodegeneration: a question of balancePeripheral androgen receptor gene suppression rescues disease in mouse models of spinal and bulbar muscular atrophy.Disruption of nongenomic testosterone signaling in a model of spinal and bulbar muscular atrophy.Therapeutic approaches to spinal and bulbar muscular atrophyMicroarray analysis of gene expression by skeletal muscle of three mouse models of Kennedy disease/spinal bulbar muscular atrophyAndrogen receptor and Kennedy disease/spinal bulbar muscular atrophyMacroautophagy is regulated by the UPR-mediator CHOP and accentuates the phenotype of SBMA mice.Neuronal SUMOylation: mechanisms, physiology, and roles in neuronal dysfunction.Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy.Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy (SBMA).Absence of disturbed axonal transport in spinal and bulbar muscular atrophy.Huntington's disease: revisiting the aggregation hypothesis in polyglutamine neurodegenerative diseases.Clinical features of spinal and bulbar muscular atrophy.Neurogenic and myogenic contributions to hereditary motor neuron disease.Current status of treatment of spinal and bulbar muscular atrophy.Abnormalities in cortical and peripheral excitability in flail arm variant amyotrophic lateral sclerosisA polyglutamine expansion disease protein sequesters PTIP to attenuate DNA repair and increase genomic instability.Pattern Differences of Small Hand Muscle Atrophy in Amyotrophic Lateral Sclerosis and Mimic Disorders.Skeletal muscle in motor neuron diseases: therapeutic target and delivery route for potential treatments.The androgen receptor's CAG/glutamine tract in mouse models of neurological disease and cancer.Mitochondrial abnormalities in spinal and bulbar muscular atrophyEthnic variation in allele distribution of the androgen receptor (AR) (CAG)n repeat.Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy.Altered RNA splicing contributes to skeletal muscle pathology in Kennedy disease knock-in mice.B2 attenuates polyglutamine-expanded androgen receptor toxicity in cell and fly models of spinal and bulbar muscular atrophy.Pathogenesis-targeting therapeutics for spinal and bulbar muscular atrophy (SBMA).Targets and consequences of protein SUMOylation in neurons.New routes to therapy for spinal and bulbar muscular atrophy.Polyglutamine androgen receptor-mediated neuromuscular disease.Exogenous Hsc70, but not thermal preconditioning, confers protection to motoneurons subjected to oxidative stress.Naratriptan mitigates CGRP1-associated motor neuron degeneration caused by an expanded polyglutamine repeat tract.
P2860
Q24187399-877F74A7-2317-4609-8F72-3DC5ACF30D2AQ24673304-9EB426BD-877F-47D2-BD22-146062305ECEQ28275894-94419D77-16DF-4497-93AE-97F9E512C1F9Q30405294-FC13BFC6-D495-444E-998A-B8868664ED35Q33636403-44385B11-2242-4BBC-8137-A76AB2744BAAQ33701169-88233C4A-43AB-4E55-8956-9497DE2576C4Q33707651-BD1DF14B-AEE9-4662-A38C-7B417F1FC319Q33904073-87C3AF1C-BFC7-4CE0-9633-B59F0E01FA96Q34055364-32AF6D1A-8DE5-4A91-9505-09F446AE863EQ34295237-A7A194EC-01D8-4138-B23D-07C60227EBFBQ34605081-83FA3143-3C9D-4B7C-ADDD-CCBF0EAB16AFQ34637225-3AB70E1E-EF56-47F9-A511-27ABE9AAF09CQ34766996-A9CD1AC5-971F-46CB-8929-69F2B30B36ABQ34797845-03A9A32D-50B4-4CA8-959A-EB87892605CAQ35008921-E38EEFB1-8576-4CC3-99F6-5B9C857E1168Q36013982-7C855131-F94A-4F9C-80FD-7F6244593957Q36037644-F4430AB1-F698-4DF8-9C6F-1AEAAFFEFB05Q36227125-DEA747A6-A2C2-4884-9F79-E6DAE6C74A51Q36231685-B330A734-D3B6-4AB6-90E0-3348CC8DCA6BQ36760958-6FFE47CF-655E-4AB7-92FF-547A2DF23714Q36805205-8E0E3F70-806E-4B30-BE5F-03EC5071EACAQ37074481-F7AA5D07-14F8-4CF9-B485-DDC95D633BBDQ37102121-088342AB-C81D-4E72-88B5-BE518BA681CCQ37323212-79C3DE3B-E245-41C0-ADB1-F72AF56B6EABQ37328024-A4566505-4839-4C1E-A77F-E71B4F92304EQ37331263-5BC28CCC-12FD-450E-ADEE-A65E56FE47D4Q37435253-726A6E10-BEDC-4499-BD5C-8CEA54DC58F3Q37503682-53F7DF5A-4AAE-424B-AEAA-DF0C296D6489Q37728628-E9A3A6EE-9E5D-43AA-85F8-62D350C0213DQ38082664-E9D7FBF6-83E7-4A08-A6D6-C9A9B9E02039Q38836469-67EFAA9C-18EA-4DD1-ACF9-1EE0B29E20F0Q46964976-73A74914-F966-4B22-8A00-DA8E57A56518Q54480739-653D60DA-9A43-40B8-BD88-E9FBDE3ACC4B
P2860
Pathogenesis, animal models and therapeutics in spinal and bulbar muscular atrophy (SBMA).
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Pathogenesis, animal models an ...... ulbar muscular atrophy (SBMA).
@ast
Pathogenesis, animal models an ...... ulbar muscular atrophy (SBMA).
@en
type
label
Pathogenesis, animal models an ...... ulbar muscular atrophy (SBMA).
@ast
Pathogenesis, animal models an ...... ulbar muscular atrophy (SBMA).
@en
prefLabel
Pathogenesis, animal models an ...... ulbar muscular atrophy (SBMA).
@ast
Pathogenesis, animal models an ...... ulbar muscular atrophy (SBMA).
@en
P2093
P1476
Pathogenesis, animal models and therapeutics in spinal and bulbar muscular atrophy (SBMA)
@en
P2093
Fumiaki Tanaka
Keisuke Suzuki
Manabu Doyu
Masahiro Waza
Masahisa Katsuno
P356
10.1016/J.EXPNEUROL.2006.01.021
P407
P577
2006-03-02T00:00:00Z